Familial Mediterranean Fever

How Does FMF Develop?

FMF develops when inherited MEFV gene changes disrupt the body’s normal control of inflammation. The MEFV gene helps produce pyrin, a protein involved in innate immune regulation. Certain variants make inflammatory pathways activate too easily, especially pathways involving interleukin-1. This causes sudden inflammation without an infection or external injury. The inflammation often affects membranes surrounding the abdomen, lungs, and joints. Therefore, patients experience repeated fever, abdominal pain, chest pain, or joint swelling. Attacks usually resolve spontaneously, but inflammation may continue silently between episodes. Persistent inflammation increases the risk of long-term complications without effective treatment.

Is Familial Mediterranean Fever a Genetic Disease?

Yes, Familial Mediterranean Fever is an inherited autoinflammatory disease associated mainly with changes in the MEFV gene. FMF is usually inherited through an autosomal recessive pattern. This means disease-causing variants are commonly inherited from both parents. However, some symptomatic patients have only one detectable MEFV variant. Others may have no clearly identified variant despite typical clinical findings. Genetic results must therefore be interpreted alongside symptoms, family history, and laboratory findings. Parents carrying a variant may have no symptoms themselves. Genetic counselling can explain inheritance risks, family testing, and future pregnancy considerations.

Who Is More Likely to Develop FMF?

FMF is more common among people with Mediterranean or Middle Eastern ancestry and those with an affected family member. Higher rates occur among Turkish, Armenian, Arab, and Sephardic Jewish populations. The condition also appears in North African, Greek, Italian, and other communities. However, Familial Mediterranean Fever can affect people from any ethnic background. Risk increases when close relatives have recurrent unexplained fevers or confirmed MEFV variants. Symptoms usually begin during childhood or adolescence. Most affected people develop attacks before age twenty. Ethnic background can support clinical suspicion, but it should never determine diagnosis alone.

What Are the Symptoms of Familial Mediterranean Fever?

Familial Mediterranean Fever usually causes recurrent fever with abdominal, chest, or joint pain during short inflammatory attacks.

• Fever often begins suddenly and may be accompanied by chills, fatigue, or headache.
• Abdominal inflammation can cause severe pain, tenderness, bloating, nausea, or constipation.
• Chest inflammation may cause sharp pain that worsens during deep breathing.
• Joint involvement commonly affects the ankles, knees, or hips and may cause swelling.
• Some patients develop a red, tender rash, usually over the lower legs.

Symptoms typically disappear between attacks. However, low-level inflammation may continue without obvious discomfort.

How Do FMF Attacks Develop?

FMF attacks develop when the innate immune system suddenly produces an excessive inflammatory response without infection. An episode often begins rapidly with fever, fatigue, or pain in one body area. Inflammation may involve the abdominal lining, lung lining, joints, skin, or surrounding tissues. Most attacks last between one and three days before resolving naturally. Attack frequency varies greatly between patients and throughout life. Stress, infections, menstruation, intense exercise, cold exposure, and missed treatment may contribute. However, many episodes occur without an identifiable trigger. Regular colchicine treatment reduces attacks and controls inflammation between episodes.

What Causes Abdominal Pain in Familial Mediterranean Fever?

Abdominal pain in Familial Mediterranean Fever usually results from temporary inflammation of the abdominal lining, called peritonitis. This inflammation irritates the membrane surrounding the abdominal organs. Pain may become severe, widespread, and sensitive to movement or touch. Nausea, vomiting, constipation, or abdominal rigidity can accompany an attack. These symptoms may resemble appendicitis, gallbladder disease, or another surgical emergency. FMF abdominal pain commonly resolves within one to three days. However, new or unusual pain should not automatically be attributed to FMF. Urgent assessment is necessary when pain persists, localizes strongly, or includes concerning symptoms.

Does FMF Cause Chest Pain?

Yes, FMF can cause chest pain when inflammation affects the lining around the lungs or, less commonly, the heart. Lung-lining inflammation is called pleuritis and usually causes sharp, one-sided pain. The discomfort often worsens with deep breathing, coughing, or movement. Some patients breathe shallowly because full breaths increase pain. These episodes generally improve within one to three days. Rarely, inflammation may affect the membrane surrounding the heart, causing pericarditis. Chest pain can also signal unrelated heart or lung emergencies. Immediate medical evaluation is important for severe pain, breathlessness, fainting, or persistent symptoms.

What Causes Joint Pain in Familial Mediterranean Fever?

Joint pain in FMF occurs because sudden sterile inflammation develops inside or around one or more joints. The ankles, knees, and hips are commonly affected. A joint may become painful, swollen, warm, and difficult to move. Joint attacks often involve one large lower-limb joint. They may follow prolonged walking, intense exercise, or physical strain. Most episodes resolve without permanent damage, although recovery can take longer than other FMF symptoms. A smaller group develops prolonged arthritis or exercise-related leg pain. Persistent swelling requires evaluation because infection, injury, or another rheumatic condition may cause similar symptoms.

Symptoms of Familial Mediterranean Fever in Children

Children with Familial Mediterranean Fever commonly experience repeated fever attacks with abdominal, chest, joint, or leg pain. Fever may appear suddenly and disappear within one to three days. Abdominal pain can be severe and may resemble appendicitis. Joint swelling often affects the ankles or knees and may limit walking. Chest pain can worsen when the child breathes deeply. Younger children may show irritability, tiredness, poor appetite, or reduced activity. A red, tender rash can also appear over the lower legs. Children are usually well between attacks. Recurrent unexplained episodes should be assessed by pediatric rheumatology.

Can Familial Mediterranean Fever Occur in Babies?

Yes, Familial Mediterranean Fever can begin during infancy, although recognizing typical attacks in babies can be difficult. Babies cannot describe abdominal, chest, or joint pain clearly. Early signs may include repeated unexplained fever, irritability, poor feeding, vomiting, or reduced movement. Some infants may cry when touched or resist moving a painful leg. Episodes usually resolve, and the baby may seem completely well afterward. Many infections cause similar symptoms during infancy. Therefore, doctors review attack patterns, family history, inflammation tests, and other possible causes. Genetic testing may support diagnosis when clinical findings remain uncertain.

How Does FMF Progress in Adults?

FMF in adults usually continues as recurrent inflammatory attacks separated by symptom-free periods. Many adults were symptomatic during childhood but received a later diagnosis. Others develop their first recognized attacks after adolescence. Attack frequency and severity can change over time. Some adults experience mainly abdominal pain, while others have chest, joint, skin, or muscle symptoms. Uncontrolled inflammation may remain active between obvious attacks. This increases the importance of regular blood and urine monitoring. Daily colchicine usually reduces attacks and prevents complications. Adults with persistent symptoms despite treatment require specialist review for adherence, dosage, alternative diagnoses, or additional therapy.

How Is Familial Mediterranean Fever Diagnosed?

Familial Mediterranean Fever is diagnosed mainly through characteristic attacks, clinical history, examination, and supportive laboratory findings. Doctors assess fever duration, symptom patterns, family history, ancestry, and symptom-free intervals. Blood tests during attacks usually show increased inflammatory markers. These changes are helpful but are not specific to FMF. Urine testing checks for protein that may indicate kidney involvement. MEFV genetic testing can support or confirm the diagnosis. However, a negative or inconclusive result does not always exclude FMF. Doctors also rule out infection, inflammatory bowel disease, PFAPA, autoimmune disease, and surgical causes. Specialist evaluation improves diagnostic accuracy.

Is Genetic Testing Necessary for FMF?

Genetic testing is helpful for FMF diagnosis, but it is not required in every patient with a typical clinical pattern. Testing identifies disease-associated variants in the MEFV gene. It is especially useful for atypical symptoms, early childhood cases, uncertain diagnoses, and family counselling. Two pathogenic variants strongly support the diagnosis. However, some clinically diagnosed patients have only one detectable variant. Others have negative results because available testing cannot identify every relevant change. Therefore, genetic testing should not replace clinical assessment. Results require careful interpretation by experienced physicians. Family testing may be considered when findings affect diagnosis, counselling, or treatment decisions.

Which Tests Are Performed for Familial Mediterranean Fever?

FMF evaluation uses clinical assessment, inflammation tests, urine testing, and sometimes MEFV genetic analysis.

• A complete blood count may show increased white blood cells during attacks.
• CRP and ESR help measure the intensity of systemic inflammation.
• Serum amyloid A can detect ongoing inflammation and assess amyloidosis risk.
• Urinalysis and urine protein measurements screen for early kidney involvement.
• Kidney and liver tests support treatment safety and complication monitoring.
• MEFV testing can identify variants supporting a genetic diagnosis.
• Imaging may exclude appendicitis, infection, or other causes when necessary.

No single laboratory test diagnoses every FMF case.

Differences Between Familial Mediterranean Fever and PFAPA

FMF and PFAPA are recurrent fever disorders, but their typical symptoms, timing, genetics, and treatments differ. PFAPA usually begins before age five and causes regular fever episodes. Mouth ulcers, sore throat, and swollen neck lymph nodes are characteristic. PFAPA attacks often last several days and follow a predictable pattern. FMF more often causes abdominal, chest, or joint inflammation. FMF attacks commonly last one to three days and may occur irregularly. MEFV variants and Mediterranean ancestry support FMF, while PFAPA has no single diagnostic gene. Overlap can occur, especially in children. Pediatric rheumatology assessment may be necessary for accurate distinction.

Differences Between Familial Mediterranean Fever and Rheumatic Diseases

FMF differs from many rheumatic diseases because it causes brief autoinflammatory attacks rather than continuous autoimmune inflammation. FMF primarily involves the innate immune system and usually creates symptom-free intervals. Many autoimmune rheumatic diseases involve adaptive immunity and may cause persistent joint, skin, or organ symptoms. Autoantibodies can support certain autoimmune diagnoses, but they are not typical FMF markers. FMF arthritis often affects one large lower-limb joint during an attack. Rheumatoid arthritis usually causes longer-lasting, symmetrical small-joint inflammation. However, FMF can coexist with other rheumatic conditions. Persistent symptoms between attacks require specialist assessment and broader testing.

When Is Biological Drug Treatment Needed for Familial Mediterranean Fever?

Biological treatment is considered when FMF remains active despite the highest tolerated colchicine dose and confirmed regular use. It may also be necessary when colchicine causes serious intolerance or cannot be used safely. Ongoing attacks, elevated inflammatory markers, or persistent serum amyloid A suggest inadequate control. Interleukin-1 inhibitors are the main biological options for colchicine-resistant FMF. Commonly used agents include anakinra and canakinumab. Treatment decisions require rheumatology supervision and individualized risk assessment. Screening for infections and appropriate vaccination planning may be required. Colchicine is often continued because it helps protect against AA amyloidosis.

How Should FMF Patients Eat?

FMF patients should follow a balanced diet because no specific food plan has proven to control the disease independently. A Mediterranean-style pattern can support general cardiovascular, digestive, and metabolic health. Meals may emphasize vegetables, fruit, legumes, whole grains, olive oil, fish, and suitable protein sources. Highly processed foods, excessive salt, added sugars, and saturated fats should be limited. Patients should drink enough water and maintain a healthy weight. Individual foods may appear to trigger symptoms, but evidence remains limited. Keeping a food and attack diary can identify personal patterns. Dietary changes should never replace prescribed colchicine.

How Can Familial Mediterranean Fever Attacks Be Reduced?

FMF attacks are reduced most effectively through regular colchicine use and consistent specialist monitoring. Colchicine should be taken daily exactly as prescribed, including symptom-free periods. Skipping doses can allow attacks and silent inflammation to return. Patients may also track personal triggers, including stress, infections, sleep loss, menstruation, or intense exercise. Balanced activity, adequate sleep, hydration, and early infection management can support overall control. Blood, urine, and serum amyloid A monitoring helps detect hidden inflammation. Persistent attacks require review of adherence, dosage, drug interactions, and alternative diagnoses. Medication doses should never be changed without medical advice.

What Happens If Familial Mediterranean Fever Is Left Untreated?

Untreated Familial Mediterranean Fever can cause recurrent painful attacks, persistent inflammation, and serious long-term organ damage. The most important complication is AA amyloidosis. This condition develops when inflammatory proteins accumulate in tissues, especially the kidneys. Protein may appear in the urine before kidney function declines. Untreated disease may also cause chronic arthritis, prolonged muscle pain, or reduced daily functioning. Repeated severe attacks can lead to unnecessary surgery when abdominal symptoms resemble emergencies. Effective colchicine treatment greatly lowers attack frequency and amyloidosis risk. Regular monitoring remains necessary, even when attacks seem mild or infrequent.

What Is the Risk of Amyloidosis in FMF?

Amyloidosis is a serious FMF complication caused by prolonged uncontrolled inflammation and sustained serum amyloid A production. The resulting AA amyloid deposits most often damage the kidneys. Early signs may include protein in the urine without noticeable symptoms. Progressive disease can cause swelling, declining kidney function, and kidney failure. Risk increases with poor inflammatory control, missed colchicine doses, severe disease, and certain genetic backgrounds. Family history may also influence risk. Daily colchicine significantly reduces the likelihood of AA amyloidosis. Regular urine protein, kidney function, CRP, and serum amyloid A monitoring supports early detection and prevention.

Is Familial Mediterranean Fever a Lifelong Disease?

Yes, Familial Mediterranean Fever is a lifelong genetic condition, although effective treatment can control symptoms and prevent complications. The underlying MEFV-related tendency does not disappear with age. Attack frequency may change, and some patients experience long symptom-free periods. However, silent inflammation can continue even when noticeable attacks are absent. Daily colchicine is therefore usually continued long term or lifelong. Treatment adherence helps prevent AA amyloidosis and kidney damage. Patients should receive regular clinical, blood, and urine monitoring. With appropriate management, most people can maintain normal education, work, family life, and daily activities.